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Antioxidant treatment with coenzyme Q-ter  
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Il trattamento antiossidante con coenzima Q-ter previene il danno ototossico  
da gentamicina nel modello animale
A.R. Fetoni, S.L.M. eRAMo1, R. RoLeSi, D. tRoiAni1, G. PALuDetti
institute of otolaryngology and 1 Human Physiology, Catholic university of Rome, italy 
SummAry
Aminoglycosides, such as gentamycin, are well known ototoxic agents. Toxicity occurs via an activation process involving the formation 
of an iron-gentamycin complex with free radical production. Antioxidants like Q-ter (a soluble formulation of coenzyme Q10, CoQ10), can 
limit or prevent cellular ototoxic damage. The present study was designed to investigate the possible protective effects of Q-ter on gen-
tamycin ototoxicity in albino guinea pigs (250-300 g). Animals were divided into five experimental groups: i, a sham control group given 
an intra-peritoneal (i.P.) injection of 0.5 ml saline (ShAm); ii, gentamycin group (gm), treated with an injection of gentamycin (100 mg/
kg); iii, gentamycin + Q-ter group (gm+Q-ter), treated with gentamycin (same dose as group ii) and an i.P. injection of coenzyme Q10 
terclatrate (Q-ter) at 100 mg/kg body weight; iV, injected with gentamycin (100 mg/kg) plus saline; V, treated with Q-ter alone (100 mg/
kg). All animals were treated for 14 consecutive days. Auditory function was evaluated by recording auditory brainstem responses (ABr) 
at 15 and 30 days from the beginning of treatment. morphological changes were analyzed by rhodamine-phalloidine staining. gentamycin-
induced progressive high-frequency hearing loss of 45-55 dB SPl. Q-ter therapy slowed and attenuated the progression of hearing loss, 
yielding a threshold shift of 20 dB. The significant loss of outer hair cells (ohCs) in the cochlear medio-basal turn in gentamycin-treated 
animals was not observed in the cochleae of animals protected with Q-ter. This study supports the hypothesis that Q-ter interferes with 
gentamycin-induced free radical formation, and suggests that it may be useful in protecting ohC function from aminoglycoside ototoxicity, 
thus reducing hearing loss.
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riASSunTo
È ben noto che gli antibiotici aminoglicosidi, tra cui la gentamicina, hanno una spiccata ototossicità che si verifica attraverso il legame fer-
ro-gentamicina con l’attivazione di una cascata intracellulare e mitocondriale che porta alla produzione di radicali liberi. Gli antiossidan-
ti come il Q-ter (forma idrosolubile del coenzima Q10), potrebbero limitare o prevenire il danno ototossico. Questo studio ha come obiettivo 
quello di indagare il possibile ruolo protettivo del Q-ter sull’ototossicità indotta da gentamicina. Come modello sperimentale sono state 
impiegate cavie albine di peso compreso tra 250-300 g. Gli animali sono stati divisi in modo casuale in cinque gruppi: gruppo I (Sham, 
controllo), animali trattati con una dose di soluzione fisiologia 0,5 ml somministrata per via intraperitoneale (I.P.): gruppo II GM, animali 
trattati con gentamicina (GM) somministrata con una iniezione intramuscolare (IM) ad una dose di 100 mg/kg; gruppo III GM+Q-ter, 
animali trattati con gentamicina (IM100 mg/kg) + Coenzima Q10 Terclatrato (Q-ter) ad una dose di 100 mg/kg I.P.; gruppo IV (controllo 
farmaco), animali trattati con gentamicina IM+ la soluzione fisiologia I.P.; gruppo V (controllo antiossidante), animali trattati con il solo 
Q-ter 100 mg/kg I.P. Tutti gli animali sono stati trattati per 14 giorni consecutivi. La funzione uditiva è stata valutata mediante la registra-
zione dei potenziali evocati uditivi del tronco dell’encefalo (ABR) a 15 e 30 giorni dall’inizio del trattamento. La tecnica di marcatura con 
Rodamina-Falloidina è stata impiegata per studiare le modificazioni morfologiche delle cellule. La gentamicina induce un innalzamento di 
soglia uditiva di circa 45-55 dB nel range delle alte frequenze che il trattamento con il Q-ter attenua di circa 20 dB. Inoltre, negli animali 
trattati con gentamicina si osserva, dopo 30 giorni dal trattamento, una perdita di cellule ciliate esterne che procede dalla prima alla terza 
fila; la prevenzione farmacologica con Q-ter previene in modo significativo la morte cellulare nel giro mediobasale della coclea. Questo 
studio dimostra l’ipotesi secondo cui il Q-ter è in grado di prevenire la formazione di radicali liberi indotta da gentamicina proteggendo, 
in questo modo, le cellule ciliate esterne dall’ototossicità indotta da amminoglicosidici e riducendone così la perdita uditiva. 
PArole ChiAVe: Antibiotici amminolgicosidici • Gentamicina • Ototossicità • Terapia antiossidante • Coenzima Q10 • Cellule ciliate 
esterne
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Introduction
numerous external agents, including high-intensity noise 
and  various  drugs  such  as  aminoglycoside  antibiotics, 
damage  hair  cells  and/or  supporting  cells  of  the  inner 
ear 1 2. however, the aminoglycoside antibiotic gentamy-
cin provides benefits that often outweigh the risks: its 
ototoxicity is a dose-limiting side effect, and the trans-
tympanic injection of gentamycin is widely used for the 
treatment  of  ménière’s  disease 1. Although  the  mecha-
nisms underlying gentamycin-induced cytotoxicity have 
not been understood in detail, drug-induced apoptosis in 
the cochlea often contributes to ototoxicity 3 4. despite dif-
ferences in the initial targeted compartments of the inner 
ear by the interactions of ototoxic drugs and damaging 
noise, these agents ultimately seem to produce similar cel-
lular pathologies and likely have overlapping mechanisms 
of action, perhaps including activation of the same cellu-
lar signalling pathways that lead to cell death 5. exposure 
to aminoglycosides or acoustic trauma leads to oxidative 
stress and production of reactive oxygen species (roS) 
which trigger an apoptotic signalling pathway 4 6.
Taken together, there is substantial evidence that oxidative 
damage and mitochondrial dysfunction may play a key 
role in sensorineural hearing loss caused by aminoglyco-
side ototoxicity and noise 7 8.
The mitochondrial respiratory chain is a powerful source 
of roS, and oxidative stress triggers the opening of the 
mitochondrial permeability transition pores that causes 
the collapse of inner mitochondrial membrane potential 
and release of pro-apoptotic factors. ubiquinone 50 or 
coenzyme Q10, (CoQ10) is a mobile electron carrier in the 
mitochondrial electron transport chain (eTC) that is the 
major source of ATP in the mitochondria. it participates in 
the eTC by carrying electrons from complex i (succinate-
ubiquinone oxidoreductase) to complex iii (ubiquinone-
cytochrome  C  oxidoreductase).  within  mitochondria, 
ubiquinone is reduced by the respiratory chain to its ac-
tive ubiquinol form, which is an effective antioxidant that 
prevents lipid peroxidation and mitochondrial damage 9. 
in a previous report, we demonstrated that idebenone, a 
synthetic analogue of CoQ10, attenuates hearing loss in a 
guinea pig model of acoustic trauma by virtue of its anti-
oxidant properties 10. it has been suggested that its effi-
cacy depends on the ability to intercept free radicals in 
both aqueous phases and lipid-water interfaces 11. in fact, 
the mobility of the agent in membranes and lipoproteins 
plays a key role in determining its antioxidant activity. 
we have further addressed the protective role of CoQ10 
in the same acoustic trauma model by comparing the ef-
ficacy of the native lypophilic CoQ10 molecule with that 
of a multi-composite formulation of CoQ10 with high wa-
ter solubility and oral bioavailability, namely, coenzyme 
Q10 terclatrate (Q-ter), and we have provided functional 
and morphological evidence on the potential efficacy of 
Q-ter in preventing oxidative injuries that result from mi-
tochondrial dysfunction 12. Q-ter consist of an outer case 
(an inactive pharmaceutical grade exipient), entrapping 
CoQ10 moieties and an aminoacid that serves as a cata-
lyst to enable the formation of the multicomposite. This 
formulation has proven to be about 200 times more solu-
ble and approximately 5 times more antioxidant capable 
than native CoQ10
 12.
Considering that CoQ10 serves as an important cofactor in 
the electron transport chain 13, and serves as an important 
antioxidant in both mitochondria and lipid membranes, 
the objective of this study was to assess the efficacy of the 
enhanced formulation of CoQ10 (Q-ter) in the prevention 
or slowdown of gentamycin-induced cochlear damage.
Materials and methods
Animals
Adult hartley albino guinea pigs (3 months old), weigh-
ing 250-300 g, with normal Preyer’s reflex, were used in 
the study. All procedures on animal use and care were 
conducted  in  accordance  with  the  laboratory  of Ani-
mal Care and use Committee of the Catholic university, 
School of medicine of rome, and of the european Com-
munities Council directive (86/609/eeC) and were ap-
proved by the italian department of health (ministero 
della Salute).
eighteen guinea pigs were randomly separated into five 
groups: i) sham control group undergoing intra-peritoneal 
(i.P.) injection with 0.5 ml saline (ShAm; n = 4); ii) gen-
tamycin group (gm; n = 4), treated with an injection of 
gentamycin (100 mg/kg body weight [b.w]); iii) gentamy-
cin + Q-ter group (gm+Q-ter; n = 4), treated with gen-
tamycin (same dose as group ii) and with i.P. injection of 
coenzyme Q10 terclatrate (Q-ter) (100 mg/kg b.w); iV) con-
trol group injected with gentamycin plus saline (n = 3) 
at the same dose as group ii; V) control animals treated 
with Q-ter alone (n = 3) at the same dose of group iii. All 
animals were treated daily for 14 consecutive days, the ad-
ministration of Q-ter was given 1 hour before gentamycin. 
The animals were housed in separate cages in temperature-
controlled rooms, with a 12-hour light-dark cycle, and had 
free access to commercial food and water.
Drug preparation
gentamycin was used as a sulphate salt dissolved in saline 
at a dose of 127 mg per 2 ml corresponding to 40 mg/ml 
of gentamycin (gentalyn® Schering Plough SpA, milan, 
italy). Q-ter is a terclatrate substance, obtained by mech-
ano-physical activation: a solid-state procedure that brings 
different substances into supramolecular contact through 
the administration of energy, and turning a simple mixture 
into a multi-composite material (Applicant, Asoltech Srl, 
Trieste, italy). Q-ter consists of an outer case (an inac-
tive pharmaceutical grade excipient) that entraps CoQ10 Coenzyme Q-ter in prevention of gentamycin ototoxicity
105
moieties (10% w/w) and an aminoacid that serves as a 
catalyst to enable the formation of the multicomposite. Q-
ter was provided by Scharper Therapeutics, milan, italy, 
and was manufactured using an industrially available na-
tive CoQ10 (Kaneka Pharma europe, Brussels, Belgium). 
For the purposes of treatment, Q-ter was dissolved in sa-
line and injected intraperitoneally at a dose of 100 mg/
kg body weight, corresponding to 10 mg/kg CoQ10. The 
Q-ter saline solution was prepared fresh daily as previ-
ously described 12.
Electrophysiological measurements of auditory function
hearing function was evaluated in all animals by recording 
auditory brainstem responses (ABr) at low (2, 4 khz), mid 
(6, 8, 12 khz) and high (16, 20 khz) frequencies. ABrs 
were measured before the first drug administration and 
15 and 30 days afterwards. Animals were mildly anaes-
thetized (ketamine hydrochloride 12.5 mg/kg, xylazine 
2.5 mg/kg and acepromazine maleate 0.75 mg/kg body 
weight) and placed in a sound-proof room. Three elec-
trodes were subcutaneously inserted into the right mas-
toid (active), vertex (reference) and left mastoid (ground). 
A PC-controlled TdT System 3 (Tucker-davis Technolo-
gies, Alachua, Florida, uSA) data acquisition system with 
real time digital signal processing was used to generate the 
auditory stimulus and ABr recording. Tone bursts from 2 
to 20 khz (1 msec rise/fall time, 10 msec total duration, 
20/sec  repetition  rate)  were  presented  under  free  field 
conditions. responses were filtered (0.3-3 khz), digitized 
and averaged across 500 discrete samples at each frequen-
cy-level combination. Thresholds were determined by in-
creasing the intensity of the 5 dB tone, starting at 0 dB and 
moving up to 100 dB, until ABr response was detected. 
next, the stimulus intensity was decreased in 5 dB steps 
until the latency-appropriate response disappeared. The 
threshold value was defined as the lowest intensity able to 
evoke an appropriate ABr response 12.
Quantitative assessment of hair cell survival and coch-
leogram
After ABr testing all animals were killed by a lethal in-
jection of anaesthetic (ketamine hydrochloride 25 mg/kg, 
xylazine 5 mg/kg and acepromazine maleate 1.5 mg/kg 
body weight). Cochleae were processed for the quanti-
tative assessment of hair cell survival and cochleogram. 
The right cochleae were quickly removed from the skull 
and fixed in 10% buffered formalin for 4 hours. Cochleae 
were then dissected in 0.1 m PBS, and the organs of Corti 
were incubated with a solution containing 0.5% Triton 
X-100 and rhodamine-conjugated phalloidin (1:100 dilu-
tion; r-415, molecular Probes) for 1 hour at room tem-
perature and protected from light. At the end of incuba-
tion, all specimens were washed twice in PBS. next, the 
specimens were mounted on slides containing an antifade 
medium (Prolong gold, invitrogen P36930). Quantifica-
tion of the remaining number of hair cells and calculation 
of hair cell loss was done with the aid of the leica con-
focal microscope (TCS-SP2; leica microsystem, gmbh, 
wezlar, germany). hair cells were considered missing if 
the stereocilia bundles were absent in rhodamine-phalloi-
din-stained and/or the profiles of outer hair cells (ohCs) 
or inner hair cells (ihCs) were not detectable. The results 
were expressed as a percentage of remaining hair cells 
in ihC layer and the three rows of ohCs over the entire 
length of the cochlear duct.
Data analysis
Statistical significance of ABr and cochleogram data was 
calculated by analysis of variance (ABr: group × fre-
quency × day, three-way AnoVA with repeated meas-
ures; cochleogram: group × hCs type × cells survived 
along 20 mm, three-way AnoVA with repeated meas-
ures). when significant differences were found with the 
overall  analysis,  post-hoc  comparisons  were  assessed 
with Tukey’s test (Statistica, Statsoft, Tulsa, uSA). A p 
value < 0.05 was considered significant.
Results
Auditory function evaluation
ABrs were recorded in each animal before, and at 15 and 
30 days from the beginning of treatment (Fig. 1). Pre-
treatment baseline ABr thresholds did not differ among 
the five groups and were consistent with data previously 
obtained in our laboratory 12. The administration of Q-ter 
alone did not modify auditory threshold at each time point 
compared to group i. no differences were observed be-
tween group ii and the group of animals treated with gen-
tamycin plus saline (data not shown), and threshold val-
ues remained stable throughout the course of treatment. 
Consistent  with  data  obtained  previously  by  recording 
compound action potentials 14 15, gentamycin treatment in 
our guinea pig model (group ii, gm) determined, at day 
15 upon the end of treatment, the greatest hearing loss at 
frequencies of 6-16 khz. The average hearing threshold 
shifts with standard deviation, are shown in Figure 1C. 
in gentamycin-treated animals, at the end of treatment 
(day 15), the threshold shift was about 15-25 dB at 2 and 
4 khz, 35-45 dB at 6-16 khz and 25-30 dB at 20 khz 
(Fig. 1C). At day 30, the average threshold shift further 
increased by about 5-10 dB at low frequencies, 5-10 dB at 
6-16 khz and 10 dB at 20 khz (Fig. 1d).
in  the  animals  treated  with  gentamycin  plus  Q-ter 
(group  iii),  the  gentamycin-induced  hearing  loss  was 
greatly attenuated. namely, the threshold shift was about 
5-15 dB at low frequencies and 15-20 at mid and high 
frequencies (Fig. 1C). At day 30, the trend of threshold 
shift increase was similar to group ii (gm). however, in 
group iii (gm+ Q-ter) the threshold shift increased by 
only about 5 dB for all frequencies (Fig. 1d).A.r. Fetoni et al.
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A comparison between group gm and group gm+ Q-ter 
(Figs. 1C-d) showed that the ABr threshold shift was sig-
nificantly attenuated at all frequencies in the Q-ter group 
(post hoc analysis p < 0.03) compared to the gentamycin 
group at days 15 and 30. Specifically, at day 15 (Fig. 1C) 
there was a difference of about 10 dB at low frequen-
cies (2-6 khz), 14 dB at 8 khz, 17-20 dB at 12-16 khz 
and 10 dB at 20 khz. At day 30 (Fig. 1d), the difference 
between the two groups was about 8-10 dB at 2-8 khz, 
20 dB at 12-16 khz and 15 dB at 20 khz.
Taken together, the frequencies most affected were 12 and 
16 khz, and the ability of Q-ter to protect from gentamy-
cin ototoxic injury reached, at day 15, about 55% of pro-
tection at 12 khz (21.25 dB vs. 38.75 dB) and about 53% 
of protection at 16 khz (22.50 dB vs. 42.50 dB). A further 
6% of protection was detected at day 30 at 16 khz, lead-
ing to a total of 59% protection (23.75 dB vs. 47.50 dB). 
remarkably, Q-ter administered in parallel with the oto-
toxic gentamycin diminished hearing loss by about 50%; 
the protection was maintained for 15 days and more pro-
nounced attenuation was observed at 16 khz.
Hair cell loss
The functional data were paralleled by histological find-
ings. normal cochleograms were observed in untreated 
animals (control animals, data not shown) 15, and no sig-
nificant differences were observed between the gentamy-
cin group and the one treated with vehicle, suggesting that 
saline did not interfere with cochlear damage and protec-
tion. missing hair cells were counted in rhodamine-phal-
loidin labelled surface preparations, and the percentage 
loss of ihC and ohC was quantitatively evaluated and 
expressed as the mean for each treatment group (Fig. 2). 
in group ii (gm) (Fig. 2A), massive ohC loss and minor 
ihC disappearance were detected in the medio-basal turn 
of the cochlea. in fact, the damaged region extended from 
approximately 11-19 mm from the apex with a decreasing 
pattern in the transitional area and a typical grading from 
the first (inner row) to the third row of ohCs. in contrast, 
animals receiving Q-ter treatment group iii (gm+Q-ter) 
(Fig. 2B) had only moderate hair cell loss and narrower 
gentamycin-induced lesions, with cell damage visible be-
tween 13 and 19 mm from the apex. Specifically, in the 
first row of the basal turn of the gentamycin group (ii, 
gm) and gentamycin plus Q-ter group (iii, gm+Q-ter), 
the surviving stereocilia bundles were 59% and 74%, re-
spectively; in the second row, ohCs were missing only 
in the gentamycin group, whereas only a few cells were 
lost in gentamycin plus Q-ter group (survival values of 
62.5% and 80%, respectively). ohCs of the third row 
were occasionally affected in both groups (survival values 
of 84% for gentamycin vs. 95% for gentamycin plus Q-
ter) (Figs. 2C-d). Concerning ihCs, the damage showed 
a trend similar to ohC loss (Figs. 2C-d). in the gentamy-
cin-treated group, 73% of ohCs survived in the basal 
turn, whereas 87% of ohCs remained in the Q-ter treated 
group (Fig. 2e). ihC survival was no significantly differ-
ent between Sham and Q-ter treated group. The recovery 
of damage by concomitant Q-ter treatment is illustrated 
in Figure 2F, where it can be seen that the area of greatest 
cell loss is around 16 mm from the apex in both groups.
Taken together, ohCs and ihCs in the basal turn of the 
cochlea were mostly affected in the gentamycin group, 
whereas hair cell loss extension and width decreased with 
concomitant administration of the antioxidant Q-ter (post 
hoc analysis p < 0.005).
Fig. 1. Functional data measured with ABR. Panels A-B: 
ABR threshold values in dB (mean ± standard error) corre-
sponding to the differences between the recordings meas-
ured in sham group (triangles), gentamycin group (squares) 
and gentamycin + Q-ter group (circles) at 15 and 30 days 
from the beginning treatment respectively. Panels C-D: The 
average hearing threshold shifts (mean±standard error)  in 
GM group (squares) and GM+Q-ter group (circles), the dot-
ted line shows the recovery among group GM and group 
GM+Q-ter at days 15 and 30 respectively. Coenzyme Q-ter in prevention of gentamycin ototoxicity
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Discussion
in this study, we investigated the protective effects of 
a CoQ10 analogue, namely Q-ter, against gentamycin-
induced ototoxicity. our results showed that the con-
comitant  administration  of  Q-ter  reduced  the  extent 
of gentamycin-induced auditory impairment. The co-
chlear  histopathological  findings  correlated  with  the 
functional results obtained by ABr recordings. in gen-
tamycin-treated animals, the increase in ABr threshold 
shift at high and medium frequencies was consistent 
with a high degree (60%) of ohC loss in the basal and 
middle  turns,  as  shown  by  the  rhodamine-phalloidin 
hair cell count along the organ of Corti. The inner row 
of ohCs was mostly affected and damage to ihCs was 
also detected. Both functional and morphological re-
sults are consistent with our previous investigations on 
gentamycin toxicity 14 15 and literature data (see for re-
view 2). in the Q-ter protected group, the reduced ABr 
threshold shift in the high and medium frequencies was 
coupled with a small degree (20%) of ohC and ihC 
loss in the basal and middle turns. Taken together, Q-
ter reduces hearing loss and the extent and distribution 
of hair cell damage.
A first question to be discussed concerns the distribution of 
gentamycin toxicity in the basal-middle cochlear turns and 
in the ohC inner row and ihCs. The cochlea ohCs are 
substantially more vulnerable to insult than ihCs, whether 
the insult is from aminoglycoside ototoxicity 16, excessive 
noise 17 or presbycusis 18. Similarly, basal turn ohCs are 
more vulnerable than more apically located ohCs to the 
Fig. 2. Rhodamine-phalloidin staining and 
cochleograms. Panels A-B: Confocal images 
of surface preparations of a damaged area 
from gentamycin and gentamycin+treatment 
for  rhodamine-phalloidin  staining.  Panel 
A shows massive OHC loss and minor IHC 
disappearance, detected in the medio-ba-
sal turn of the cochlea in the group. Panel 
B shows moderate hair cell loss for OHCs 
and IHCs in gentamycin plus Q-ter treated 
animals.  Panels  C-F:  cochleograms  were 
plotted as percentage with standard devia-
tion of survival IHCs and OHCs for each row 
against distance from the apex. A gradient 
of OHC loss was observed for gentamycin 
treatment (panel C) and gentamycin+Q-ter 
treatment  (panel  D).  Quantitative  analysis 
showed that gentamycin treatment caused 
a more consistent OHC loss in a narrow re-
gion of the cochlea from 11-19 mm from 
the  apex.  Q-ter  treated  animals  had  sig-
nificantly less OHC loss than gentamycin-
treated animals in a narrower area of about 
13-19 mm from the apex. Panel E: aver-
age survival of cells in the GM (square) and 
GM+Q-ter (circles) groups. Panel F shows 
average cell loss and recovery of damage 
by concomitant Q-ter treatment in group GM 
(squares) and group GM+Q-ter (circles) and 
recovery (diamonds).A.r. Fetoni et al.
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same insults 19. however, by comparing gentamycin dam-
age with noise damage, a difference in the order of affected 
ohC rows can be observed. noise first damages the outer-
most row with grading towards the inner row; gentamycin 
affects the inner row with grading to the second and third 
outer rows 17 19 20. This histopathological data may provide 
an indication on the distribution of systemic gentamycin to 
ohCs. recent experimental studies suggest that, in vivo, 
systemically administered aminoglycosides enter cochlear 
hair cells from the endolymph prior to inducing auditory 
dysfunction 21 22. As detailed by other authors 22, there are 
two routes by which systemically-administered aminogly-
cosides could enter the endolymph: first by a trans-strial 
trafficking route from strial capillaries to marginal cells, 
followed by clearance into the endolymph, and secondly 
by crossing the blood-labyrinth barrier into the perilymph 
and then into the endolymph via (a) transcytosis across the 
epithelial perilymph/endolymph barrier or (b) trafficking of 
aminoglycosides from the perilymph domain via fibrocytes 
to the stria vascularis, to marginal cells and clearance into 
endolymph (Fig. 3, white arrow heads) 23. it is also sug-
gested that through the endolynph, the positive endolym-
phatic potential drives aminoglycosides into hair cells via 
open  mechano-transduction  channels  24  25.  Alternatively, 
aminoglycosides in the scala tympani could pass through 
the basilar membrane into extracellular fluids within the or-
gan of Corti, and from there enter hair cells by traversing 
their basolateral membranes (Fig. 3, red arrow head). The 
distribution of damage, consistent with previous investiga-
tions and literature data 14 15 19 may indirectly favours this 
last hypothesis. however, the mechanism by which gen-
tamycin reaches the endolymph and damages mostly the 
inner ohC row remains undetermined and needs further 
specific experimental approaches.
The second and main point of discussion concerns the 
mechanism of Q-ter protection against gentamycin oto-
toxicity. Q-ter is a water-soluble coenzyme Q10 formula-
tion. A therapeutic approach with native CoQ10 is limited 
by its poor bioavailability in aqueous media and stabil-
ity problems. in contrast, the Q-ter formulation is more 
Fig. 3. Suggested mechanisms of intracochlear uptake of gentamycin and intracellular pathways of damage. There are two routes by which systemically-ad-
ministered aminoglycosides could enter the endolymph: first by a trans-strial trafficking route from strial capillaries to marginal cells, and secondly by travers-
ing the blood-labyrinth barrier into perilymph and then within (white arrow heads). Alternatively, aminoglycosides pass to the scala tympani through the basilar 
membrane into extracellular fluids within the organ of Corti by traversing the basolateral membranes (red arrow head). Gentamycin enters the hair cell through 
mechano-electrical transducer channels; it forms a complex with iron (Fe), a transition metal. These redox active complexes generate ROS/RNS including the 
superoxide anion radical, hydrogen peroxide, hydroxyl radical and peroxynitrite anion. Reactive species activate JNK (c-Jun N-terminal kinase), which then 
translocate to the nucleus to activate genes in the cell death pathway by transfer to the mitochondria where they promote the release of cytochrome c (cyt c). 
In the cytosol, cyt c triggers the activation of a series of caspases followed by apoptosis (programmed cell death) via what is referred to as caspase-dependent 
cell death. In addition to this caspase-dependent apoptotic pathway, gentamycin may also kill cells via caspase-independent mechanisms.Coenzyme Q-ter in prevention of gentamycin ototoxicity
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soluble than the native molecule, the chemical moieties 
of the starting materials are preserved and physicochemi-
cal properties such as stability and antioxidant capacity 
are improved 26 27. in a previous publication 12, we demon-
strated the antioxidant efficacy of the water soluble Q-ter 
in a guinea pig model of acoustic trauma. Thus, consid-
ering that the mechanism of cochlear damage by noise 
and aminoglycosides is reported to be analogous 28, Q-ter 
protection  against  gentamycin  toxicity,  as  described  in 
the present paper, is not surprising (see suggested intra-
cellular activated pathway in the inset box of Figure 3). 
Furthermore, the role of oxidative damage and possible 
mitochondrial dysfunction in gentamycin ototoxicity can 
be indirectly hypothesized by the efficacy of our CoQ10 
formulation. CoQ10 blocks apoptosis by inhibiting acti-
vation of the mitochondrial permeability transition inde-
pendently of its free radical scavenging activity 9. Another 
potential protective mechanism of CoQ10 concerns its role 
as  an  obligatory  cofactor  of  mitochondrial  uncoupling 
proteins  29  and  the  activation  of  these  proteins  reduces 
mitochondrial-free radical generation.
There is increasing interest in the utility of CoQ10 to treat 
neurodegenerative diseases 30. CoQ10 induces mitochon-
drial uncoupling in the substantia nigra of primates, and 
this  is  associated  with  marked  neuroprotection  31.  in-
creased expression of mitochondrial uncoupling proteins 
protects against brain damage associated with both exper-
imental stroke and epilepsy 32 33. CoQ10 diminishes ischae-
mia-induced neuronal injury in the hippocampus 34, and 
protects cultured cerebellar neurons against excitotoxin-
induced degeneration 35. The potential efficacy of CoQ10 in 
the treatment of both Parkinson’s and Alzheimer’s disease 
has also been described 30.
The data in the present paper may hold additional indi-
cation on the novel therapeutic design of Q-ter and its 
potential use in combating oxidative damage induced by 
exposure to ototoxic compounds.
Acknowledgements
This research was supported by grants from the Fondi di 
Ateneo uCSC rome italy.
References
1  guthrie ow. Aminoglycoside induced ototoxicity. Toxicol-
ogy 2008;249:91-6.
2  Xie J, Talaska Ae, Schacht J. New developments in aminogly-
coside therapy and ototoxicity. hear res 2011;281:28-37.
3  Jeong Sw, Kim lS, hur d et al. Gentamycin-induced spiral 
ganglion cell death: apoptosis mediated by ROS and the JNK 
signalling pathway. Acta otolaryngol 2010;130:670-8.
4  ding d, Jiang h, Salvi rJ. Mechanisms of rapid sensory 
hair-cell death following co-administration of gentamycin 
and ethacrynic acid. hear res 2010;259:16-23.
5  Kopke r, Allen KA, henderson d, et al. A radical demise. 
Toxins  and  trauma  share  common  pathways  in  hair  cell 
death. Ann n y Acad Sci 1999;884:171-91.
6  Priuska em, Schacht J. Formation of free radicals by gen-
tamycin and iron and evidence for an iron/gentamycin com-
plex. Biochem Pharmacol 1995;50:1749-52.
7  Sergi B, Fetoni Ar, Ferraresi A, et al. The role of antioxi-
dants in protection from ototoxic drugs. Acta otolaryngol 
Suppl 2004;(552):42-5.
8  Fetoni Ar, ralli m, Sergi B, et al. Protective effects of N-
acetylcysteine on noise-induced hearing loss in guinea pigs. 
Acta otorhinolaryngol ital 2009;29:70-5.
9  Papucci l, Schiavone n, witort e, et al. Coenzyme Q10 pre-
vents apoptosis by inhibiting mitochondrial depolarization 
independently of its free radical scavenging property. J Biol 
Chem 2003;278:28220-8.
10  Sergi B, Fetoni Ar, Paludetti g, et al. Protective properties 
of idebenone in noise-induced hearing loss in the guinea pig. 
neuroreport 2006;17:857-61.
11  mordente A, martorana ge, minotti g, et al. Antioxidant 
properties of 2, 3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-
1,4-benzoquinone  (idebenone).  Chem  res  Toxicol 
1998;11:54-63.
12  Fetoni Ar, Piacentini r, Fiorita A, et al. Water-soluble Coen-
zyme Q10 formulation (Q-ter) promotes outer hair cell sur-
vival in a guinea pig model of noise induced hearing loss 
(NIHL). Brain res 2009:1257:108-16.
13  lenaz g, genova ml. Mobility and function of coenzyme 
Q (ubiquinone) in the mitochondrial respiratory chain. Bio-
chim Biophys Acta 2009;1787:563-73.
14  Fetoni Ar, Sergi B, Scarano e, et al. Protective effects of 
alpha-tocopherol  against  gentamycin-induced  Oto-ves-
tibulo  toxicity:  an  experimental  study.  Acta  otolaryngol 
2003;123:192-7.
15  Fetoni Ar, Sergi B, Ferraresi A, et al. Tocopherol protective 
effects on gentamycin ototoxicity: an experimental study. int 
J Aud 2004;43:166-71.
16  Karasawa  T,  Steyger  PS.  Intracellular  mechanisms  of 
aminoglycoside-induced  cytotoxicity.  integr  Biol  (Camb) 
2011;3:879-86.
17  Fetoni Ar, mancuso C, eramo Slm, et al. In vivo protective 
effect of ferulic acid against noise-induced hearing loss in 
the guinea-pig. neuroscience 2010;169:1575-88.
18  Fetoni Ar, Picciotti Pm, Paludetti g, et al. Pathogenesis 
of presbycusis in animal models: a review. exp gerontol 
2011;46:413-25.
19  warchol  me.  Cellular  mechanisms  of  aminoglycoside 
ototoxicity  Curr  opin  otolaryngol  head  neck  Surg. 
2010;18:454-8.
20  li h, wang Q, Steyger PS. Acoustic trauma increases co-
chlear  and  hair  cell  uptake  of  gentamycin.  PloS  one 
2011;6:e19130.
21  goodyear rJ, gale Je, ranatunga Km, et al. Aminoglyco-
side- induced phosphatidylserine externalization in sensory 
hair cells is s regionally restricted, rapid, and reversible. J 
neurosci 2008;28:9939-52.
22  wang Qi, Kachelmeier A, Steyger PS. Competitive antago-
nism of fluorescent gentamycin uptake in the cochlea. hear 
res 2010;268:250-9.A.r. Fetoni et al.
110
23  dai CF, Steyger PS. A systemic gentamycin pathway across 
the stria vascularis. hear res 2008;235:114-24.
24  Takada A, Bledsoe S Jr, Schacht J. An energy-dependent step 
in aminoglycoside ototoxicity: prevention of gentamycin oto-
toxicity during reduced. J res 1985;19:245-51.
25  marcotti w, van netten Sm, Kros CJ. The aminoglycoside 
antibiotic dihydrostreptomycin rapidly enters mouse outer 
hair cells through the mechano-electrical transducer chan-
nels. J Physiol 2005;567:505-21.
26  ou  B,  hampsch-woodill  m,  Prior  rl.  Development  and 
validation of an improved oxygen radical absorbance capac-
ity assay using fluorescein as the fluorescent probe. J Agric 
Food Chem 2001;46:4619-26.
27  Corvi mora P, Canal T, Fortuna F, et al. An innovative tech-
nology for improving solubility and antioxidant properties 
of Coenzyme Q10. oxygen Society of California Congress 
“oxidants And Antioxidants in Biology”, Alba 7-10 Septem-
ber 2005.
28  Abi-hachem rn, Zine A, Van de water Tr. The injured 
cochlea  as  a  target  for  inflammatory  processes,  initia-
tion  of  cell  death  pathways  and  application  of  related 
otoprotectives strategies. recent Pat CnS drug discov 
2010;5:147-63.
29  echtay KS, murphy mP, Smith rA, et al. Superoxide ac-
tivates  mitochondrial  uncoupling  protein  2  from  the  ma-
trix side. Studies using targeted antioxidants. J Biol Chem 
2002;277:47129-35.
30  Beal mF. Mitochondrial dysfunction and oxidative damage in 
Alzheimer’s and Parkinson’s diseases and coenzyme Q10 as 
a potential treatment. J Bioenerg Biomembr 2004;36:381-6.
31  horvath Tl, diano S, leranth C, et al. Coenzyme Q induces 
nigral mitochondrial uncoupling and prevents dopamine cell 
loss in a primate model of Parkinson’s disease. endocrinol-
ogy 2003;144:2757-60.
32  mattiasson i, lethagen S, hillarp A. Increased sensitivity to 
ADP-aggregation in aspirin treated patients with recurrent 
ischemic stroke? int Angiol 2003;22:239-42.
33  Sullivan Pg, dubé C, dorenbos K, et al. Mitochondrial un-
coupling protein-2 protects the immature brain from excito-
toxic neuronal death. Ann neurol 2003;53:711-7.
34  ostrowski rP. Effect of coenzyme Q(10) on biochemical and 
morphological changes in experimental ischemia in the rat 
brain. Brain res Bull 2000;53:399-407.
35  Favit A, nicoletti F, Scapagnini u, et al. Ubiquinone protects 
cultured neurons against spontaneous and excitotoxin-induced 
degeneration. J Cereb Blood Flow metab 1992;12:638-45.
Address  for  correspondence:  diana Troiani,  institute  of  human 
Physiology,  Catholic  university  of  rome,  largo  Francesco Vito 
1, 00168 rome, italy. Tel. +39 06 30154966. e-mail: d.troiani@
rm.unicatt.it
received: September 27, 2011 - Accepted: december 22, 2011